Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Capricor Therapeutics Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
CAPR
Nasdaq
2836
https://capricor.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Capricor Therapeutics Inc
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
- Mar 25th, 2024 1:55 pm
Capricor Therapeutics to Present at Upcoming Investor Conferences
- Mar 21st, 2024 12:30 pm
Earnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
- Mar 14th, 2024 11:30 am
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
- Mar 13th, 2024 1:40 pm
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
- Mar 7th, 2024 2:55 pm
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
- Mar 6th, 2024 1:30 pm
Capricor Therapeutics Full Year 2023 Earnings: Beats Expectations
- Mar 3rd, 2024 12:41 pm
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcript
- Mar 2nd, 2024 1:17 pm
Q4 2023 Capricor Therapeutics Inc Earnings Call
- Mar 1st, 2024 11:06 am
Capricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD Therapy
- Feb 29th, 2024 9:42 pm
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Feb 29th, 2024 9:05 pm
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
- Feb 27th, 2024 1:30 pm
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
- Feb 22nd, 2024 1:30 pm
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
- Feb 20th, 2024 1:30 pm
Market Sentiment Around Loss-Making Capricor Therapeutics, Inc. (NASDAQ:CAPR)
- Feb 4th, 2024 1:31 pm
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
- Jan 24th, 2024 2:15 pm
Capricor Therapeutics (NASDAQ:CAPR) shareholders are up 16% this past week, but still in the red over the last five years
- Dec 13th, 2023 4:41 pm
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
- Dec 11th, 2023 2:00 pm
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?
- Nov 16th, 2023 3:42 pm
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript
- Nov 16th, 2023 1:28 pm
Scroll